Cumberland Pharmaceuticals Inc (CPIX) — 分析摘要
Cumberland Pharmaceuticals Inc(CPIX)的市值为97.99百万美元,最近一年的营收同比增长了+17.6%。净利润率为-6.4%。当前市盈率为-34.6倍。
核心要点
- 营收同比变化+17.6%
- 净利润率-6.4%
- 市盈率-34.6倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比,CPIX的营收增长为+17.6%,市盈率为-34.6倍。
Cumberland Pharmaceuticals Inc (CPIX)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗,在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 -5.6x — 盈利不足以覆盖利息支出
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.
行业
PHARMACEUTICAL PREPARATIONS
员工人数
93
总部
NASHVILLE,, TN
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
年度每股股息
N/A
股息收益率
N/A
股息历史
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。